Article Information
History
- April 7, 2021.
Article Versions
- You are currently viewing Version 1 of this article (April 7, 2021 - 09:31).
- Version 2 (April 17, 2021 - 09:37).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- David E. Garda,*,
- Mollie M. Pleetb,c,
- Ellen R. Bradleyb,c,
- Andrew Pennb,
- Matthew L. Gallensteina,
- Lauren S. Rileya,
- Meghan DellaCrossed,
- Emily Garfinklee,
- Erin E. Michalakf and
- Joshua D. Woolleyb,c
- aSan Francisco State University, San Francisco, CA USA
- bUniversity of California San Francisco, San Francisco, CA USA
- cSan Francisco Veteran’s Affairs Medical Center, San Francisco, CA USA
- dThe Wright Institute, Berkeley, CA USA
- ePalo Alto University-Pacific Graduate School of Psychology, Palo Alto, CA USA
- fUniversity of British Columbia, Vancouver, BC Canada
- ↵*Corresponding author:
David E. Gard, Ph.D., Department of Psychology, San Francisco State University, 1600 Holloway Ave, San Francisco, California 94132 USA, dgard{at}sfsu.edu
Posted April 07, 2021.
Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies
